Hemoglobin (Hgb) greater than 8.0 g/dL (may have packed red blood cell [PRBC] transfusion)
Measured within 28 days prior to registration: hemoglobin >= 10.0 g/dL with no blood transfusions (packed red blood cells in the past 28 days is permitted)
Inability to receive HCT due to alloimmunization, defined as the inability to receive packed red blood cell (pRBC) transfusion therapy.
Blood (packed red blood cells, platelets) transfusions within 1 month prior to study start
Hemoglobin >= 8 g/dL (with or without packed red blood cell [PRBC] transfusion) and documented within 14 days prior to registration and within 14 days prior to the start of treatment
Within 14 days prior to registration: Hemoglobin >= 10 g/dL; patients may be transfused packed red blood cells (PRBCs) up to 1 week prior to when enrollment labs are drawn; on study, transfusions may be given as clinically indicated
Subjects should not have packed red blood cells (PRBC) or platelet transfusion within 14 days of the screening
Hemoglobin: >= 8.0 gm/dl (may transfuse peripheral red blood cells [PRBCs])
Patients who have had a whole blood transfusion within 120 days prior to enrollment. (Packed red blood cells and platelet transfusions are acceptable)
Within two weeks prior to enrollment: Hemoglobin >= 9 gm/dL and > 7 days since last red blood cell transfusion
Hemoglobin >= 9.0 g/dL (may receive packed red blood cell [prbc] transfusion)
Hemoglobin (Hgb) >= 9 g/dL with or without packed red blood cells (pRBC) transfusion
Patients may be transfused with packed red blood cells (PRBCs) up to 7 days prior to when enrollment labs are drawn to achieve Hgb >= 9.0 mg/dL
Platelet transfusion and packed red blood cell transfusion can also be given prior to the start of treatment and treatment to achieve a target plt >= 75,000/uL and hemoglobin of >= 8.5 g/dl, provided that patients have not received growth factors for at least 14 days prior to entering trial
UROTHELIAL CARCINOMA EXPANSION COHORT: Hemoglobin >= 10 g/dL in the absence of packed red blood cells transfusion 28 days prior to dosing OR > 9 g/dL, if the value is constant across 2 readings within 2 weeks in the absence of packed red blood cells transfusion 28 days prior to dosing
Patients must have hemoglobin >= 8.5 g/dl; platelet transfusion and packed red blood cell transfusion can also be given prior to the start of treatment and during treatment to achieve a target hemoglobin of >= 8.5/ul provided that patients have not received growth factors for at least 14 days prior to entering trial
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nHemoglobin (Hgb) >= 10 g/dL in the absence of packed red blood cell transfusion 28 days prior to dosing OR Hgb 9-9.9 g/dL and the value is constant across 2 readings within 2 weeks, in the absence of packed red blood cell transfusion 28 days prior to dosing
PHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHemoglobin (Hgb) >= 9 g/dL in the absence of packed red blood cell transfusion 28 days prior to dosing
PHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT 4 ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHemoglobin (Hgb) >= 9 g/dL in the absence of packed red blood cell transfusion 28 days prior to dosing
PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nHemoglobin (Hgb) >= 9 g/dL in the absence of packed red blood cell transfusion 28 days prior to dosing
Hemoglobin >= 9 g/dL (packed red blood cell [pRBC] transfusion +/- erythropoiesis-stimulating agents [ESA] are allowed) (must be within 7 days of MLA)
Hemoglobin >= 8 g/dL (packed red blood cell [PRBC] transfusions permitted)
Hemoglobin (Hgb) greater than 8.0 g/dL (may have packed red blood cell [PRBC] transfusion)
Part 1: hemoglobin level of ? 8 g/dL within 2 weeks of enrollment\r\n* Packed red blood cell (PRBC) transfusions will be allowed to patients with hemoglobin < 8g/dl
Hemoglobin >= 8 g/dL (packed red blood cells [PRBC] transfusions permitted)
Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L, specimens must be collected within 10 days prior to the start of study treatment\r\n* Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks
Hemoglobin >= 8 g/dl (may be after transfusion of packed red blood cells or use of erythropoiesis stimulating agents)
Absence of a regular red blood cell transfusion requirement
Hemoglobin >= 8.0 gm/dL (may receive packed red blood cell [PRBC] transfusions)
Platelet or packed red blood cell transfusion within 14 days of pre-treatment evaluation
Hemoglobin >= 9 (packed red blood cells [pRBC] transfusion +/- erythropoiesis-stimulating agents [ESA] are allowed) (must be within 7 days of MLA)
Previous major bleed (bleeding requiring transfusion of red blood cells) on LMWH
Hemoglobin >= 8 g/dL (may have received packed red blood cell transfusion)
Within 14 days after subjects signed the treatment consent: Hemoglobin >= 10 g/dl; patients may be transfused packed red blood cells (PRBCs) up to 1 week prior to when enrollment labs are drawn; on study, transfusions may be given as clinically indicated
Hemoglobin >= 9 g/dl (may transfuse packed red blood cells [PRBC] to meet parameter)
Packed red blood cell or platelet transfusion within 7 days of screening laboratory tests.
Hemoglobin >= 9 g/dl without packed red blood cell dependency, unless due to bone marrow involvement with lymphoma
Red blood cell transfusion within 2 weeks prior to anticipated start of study treatment.
Anemia, Hemoglobin (Hgb) ? 9.0 g/dL or ? 2 units of Red Blood Cells (RBCs) within 84 days
Packed cell volume (PCV) >= 30 (with or without transfusion)
Hemoglobin >= 8.0 gm/dL (may receive packed red blood cell [pRBC] transfusions)